Sarepta Therapeutics (SRPT) Tops Q4 EPS by 36c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.77), $0.36 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $201.5 million versus the consensus estimate of $198.61 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance